NUVB250516P500
- 0.00
- 0.000.00%
Nuvation Bio Newsroom
JMP Securities Initiates Nuvation Bio(NUVB.US) With Buy Rating, Announces Target Price $6
JMP Securities Initiates Coverage On Nuvation Bio With Market Outperform Rating, Announces Price Target of $6
Press Release: Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025
Express News | Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025
Optimistic Outlook for Nuvation Bio: Strategic Positioning and Market Potential of Taletrectinib
Insider Purchase: PRESIDENT AND CEO of $NUVB Buys 300,000 Shares
Nuvation Bio CEO David Hung Purchases $820,220 in Company Stock
Robert Mashal Bought 100% More Shares In Nuvation Bio
Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference
Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE) and Nuvation Bio (NUVB)
Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025
Express News | Nuvation Bio Inc - Enters Supply Agreement With Asymchem for Taletrectinib - SEC Filing
Express News | Nuvation Bio to Present Matching-Adjusted Indirect Comparison Data for Taletrectinib Vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025
Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib Vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025
JonesTrading Initiates Nuvation Bio(NUVB.US) With Buy Rating, Announces Target Price $10
Nuvation Bio Initiated at Buy by Jones Trading
Nuvation Bio Price Target Announced at $10.00/Share by Jones Trading
Nuvation Bio Analyst Ratings
H.C. Wainwright Maintains Nuvation Bio(NUVB.US) With Buy Rating, Cuts Target Price to $10
Express News | Nuvation Bio Inc. : H.c. Wainwright Cuts Target Price to $10 From $11